<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00163852</url>
  </required_header>
  <id_info>
    <org_study_id>14/04</org_study_id>
    <nct_id>NCT00163852</nct_id>
  </id_info>
  <brief_title>Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis</brief_title>
  <official_title>Salt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Federation Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayside Health</source>
  <brief_summary>
    <textblock>
      Adult cystic fibrosis (CF) patients admitted with an acute infection complicated by acid-base
      disturbance and decreased ventilation will be studied.

      They will receive salt replacement to correct the acid-base disturbance and possibly their
      ventilation.

      Assessment of symptoms (questionnaire), acid-base and electrolyte status (blood and urine
      tests) ventilation (overnight oxygen and carbon dioxide monitoring non-invasively) and
      sleep-wake pattern (actigraphy) will be carried out.

      Study hypothesis: Acute volume and electrolyte replacement corrects hypochloremic hypovolemic
      metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of
      cystic fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Hypochloremic hypovolemic metabolic alkalosis contributes to hypercapnia in acute
      exacerbations of cystic fibrosis. Treatment of the metabolic alkalosis with volume and sodium
      chloride (NaCl) replacement could reduce hypoventilation and hypercapnia, thereby improving
      symptoms, sleep patterns and daytime activity level. This would avoid unnecessary treatment
      with non-invasive ventilation.

      Hypothesis: Volume and NaCl replacement corrects hypochloremic hypovolemic metabolic
      alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of cystic
      fibrosis and results in symptomatic improvement.

      Entry criteria:

        -  Adult cystic fibrosis patient

        -  Admission with acute exacerbation

        -  PaCO2 &gt; 45 mmHg

        -  Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)

        -  Serum chloride (Cl) ≤ 98 mmol/L

        -  Serum albumin (alb) &gt; 25 mmol/L

      Intervention:

        -  Normal saline intravenously day(D)1,2,3. (Replace greater of Cl deficiency or acute
           weight loss, with 2/3 on D1 and remainder D2, D3)

        -  NaCl tablets 3 tds D4 to 10 (calculated to replace 7 mmol NaCl loss in 60 kg subject)

      Random allocation to either:

        1. Intervention + standard care (including standard dietary advice) D1-10

        2. Standard care alone (including standard dietary advice) D1-10

      Primary outcome measures: (D1, D4, D10)

        -  PaCO2 (performed at same time of day as admission ABG’s)

        -  Acid-base status (Stinebaugh and Austin, ABG’s)

        -  Serum chloride

        -  Overnight oximetry (% night SpO2&lt;90%) and PtcCO2 (rise in CO2 overnight)

      Secondary outcome measures: (D1, D4, D10)

        -  Serum albumin, sodium

        -  Body mass index (BMI)

        -  Spirometry (D1, D10)

        -  Headache scale

        -  Epworth sleepiness scale

        -  Wrist actigraphy (circadian rhythm and daytime activity level)(D1-10)

        -  Urinary chloride, potassium, sodium, pH, osmolality

        -  Baseline ABG’s as stable outpatient (within 3 months, pre or post admission)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2004</start_date>
  <completion_date>February 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measures: (Day1, D4, D10)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>•PaCO2 (performed at same time of day as admission ABG’s)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>•Acid-base status (Stinebaugh and Austin, ABG’s)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>•Serum chloride</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>•Overnight oximetry (% night SpO2&lt;90%) and PtcCO2 (rise in CO2 overnight)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures: (Day1, D4, D10)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>•Serum albumin, sodium</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>•Body mass index (BMI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>•Spirometry (D1, D10)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>•Headache scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>•Epworth sleepiness scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>•Wrist actigraphy (circadian rhythm and daytime activity level)(D1-10)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>•Urinary chloride, potassium, sodium, pH, osmolality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>•Baseline ABG’s as stable outpatient (within 3 months, pre or post admission)</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline IV, salt tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult cystic fibrosis patient

          -  Admission with acute exacerbation (criteria- fall in FEV1 &gt; 10% from best in last
             12/12, change in sputum volume and colour, new pulmonary infiltrate)

          -  PaCO2 &gt; 45 mmHg on admission

          -  Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)

          -  Serum chloride (Cl) ≤ 98 mmol/L

          -  Serum albumin (alb) ≤ 25 mmol/L

        Exclusion Criteria:

        Concurrent diuretic therapy Concurrent glucocorticoid therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew T Naughton, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alan C Young, MBBS, FRACP</last_name>
    <phone>613 9276 2000</phone>
    <phone_ext>pager 4576</phone_ext>
    <email>alan.young@med.monash.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew T Naughton, MBBS, FRACP</last_name>
    <phone>613 9276 2000</phone>
    <phone_ext>3770</phone_ext>
    <email>m.naughton@alfred.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Alfred</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan C Young, MBBS</last_name>
      <phone>613 9276 2000</phone>
      <phone_ext>pager 4576</phone_ext>
      <email>alan.young@med.monash.edu.au</email>
    </contact>
    <investigator>
      <last_name>Alan C Young, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2005</last_update_posted>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Metabolic alkalosis</keyword>
  <keyword>Hypercapnia</keyword>
  <keyword>Salt replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Alkalosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

